What is GeneTex?
GeneTex operates as a critical infrastructure provider for the global scientific community, specializing in the development and distribution of high-fidelity antibodies, proteins, and lysates. The company distinguishes itself through a rigorous validation protocol, ensuring that its research reagents meet the exacting standards required by academic institutions and pharmaceutical enterprises alike. By offering a comprehensive suite of ELISA kits and custom biochemical solutions, GeneTex serves as a foundational partner for laboratories engaged in complex diagnostic and therapeutic discovery. Their commitment to quality control and scalable production capabilities positions them as a primary vendor in the high-growth biotechnology reagents market.
How much funding has GeneTex raised?
GeneTex has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in GeneTex
PPP
Public-Private Partnership
What's next for GeneTex?
With the successful acquisition of this $150K investment, GeneTex is well-positioned to accelerate its strategic roadmap. The company is expected to prioritize the expansion of its proprietary antibody validation pipeline and enhance its custom service offerings to meet the increasing demand for specialized research tools. As the firm transitions into this next phase of growth, the focus will likely shift toward optimizing supply chain logistics and deepening its penetration into international pharmaceutical research markets. This capital deployment serves as a catalyst for sustained innovation, enabling GeneTex to maintain its competitive edge while addressing the evolving technical requirements of the global biomedical research landscape.
See full GeneTex company page
